



May 3, 2011

Arrowhead Research to Present at the 2011 MDB Capital Group Bright Lights Conference on May 10

PASADENA, Calif. — May 3, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the 2011 MDB Capital Group Bright Lights Conference at 2:00 p.m. ET on Tuesday, May 10, 2011. The conference will feature over 40 of the most innovative companies with disruptive and market changing IP. The event is being held at the Le Parker Meridien Hotel in New York City.

Investors attending the conference are encouraged to schedule a one-on-one meeting at the conference with Arrowhead's CEO Dr. Christopher Anzalone by contacting Brandi Floberg at arrowres@tpg-ir.com or 212-481-2050.

About Arrowhead Research Corporation

Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapeutic products at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead addresses its target markets through focused subsidiaries, which include: Calando Pharmaceuticals, a leader in delivering small RNAs for gene silencing; Ablaris Therapeutics, an anti-obesity therapeutics company; and Nanotope, a regenerative medicine company. For more information please visit <http://www.arrowheadresearch.com>.

Contacts:
Brandi Floberg

The Piacente Group, Inc.

212-481-2050
arrowres@tpg-ir.com